| # | Title | Journal | Year | Citations |
|---|
| 1 | Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes | European Heart Journal Supplements | 2001 | 168 |
| 2 | Outline of the report on cardiovascular diseases in China, 2014 | European Heart Journal Supplements | 2016 | 115 |
| 3 | European workshop in periodontal health and cardiovascular disease--scientific evidence on the association between periodontal and cardiovascular diseases: a review of the literature | European Heart Journal Supplements | 2010 | 105 |
| 4 | The Copenhagen city heart study | European Heart Journal Supplements | 2001 | 102 |
| 5 | Why do we need observational studies of everyday patients in the real-life setting?: Table 1 | European Heart Journal Supplements | 2015 | 101 |
| 6 | Therapeutic options for patients with chronic myocardial ischaemia | European Heart Journal Supplements | 2004 | 87 |
| 7 | The burden of heart failure | European Heart Journal Supplements | 2002 | 83 |
| 8 | Overview of the cardiovascular effects of tadalafil | European Heart Journal Supplements | 2002 | 71 |
| 9 | Epidemiology and economic burden of chronic heart failure | European Heart Journal Supplements | 2004 | 71 |
| 10 | Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia | European Heart Journal Supplements | 2016 | 71 |
| 11 | Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies | European Heart Journal Supplements | 2020 | 68 |
| 12 | Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor | European Heart Journal Supplements | 2001 | 62 |
| 13 | Heart failure case disease management program: a pilot study of home telemonitoring versus usual care | European Heart Journal Supplements | 2004 | 57 |
| 14 | The revised definition of pulmonary hypertension: exploring the impact on patient management | European Heart Journal Supplements | 2019 | 55 |
| 15 | How important is blood pressure variability? | European Heart Journal Supplements | 2020 | 54 |
| 16 | n-3 Fatty acids and the inflammatory response ? biological background | European Heart Journal Supplements | 2001 | 53 |
| 17 | Haemostasis and thrombosis: an overview | European Heart Journal Supplements | 2001 | 52 |
| 18 | Ezetimibe: a selective inhibitor of cholesterol absorption | European Heart Journal Supplements | 2001 | 50 |
| 19 | Inhibition of late (sustained/ persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function | European Heart Journal Supplements | 2004 | 50 |
| 20 | Perspectives: The burden of cardiovascular risk factors and coronary heart disease in Europe and worldwide | European Heart Journal Supplements | 2014 | 49 |
| 21 | Ageing and endothelial dysfunction | European Heart Journal Supplements | 2002 | 47 |
| 22 | The burden of heart failure | European Heart Journal Supplements | 2003 | 46 |
| 23 | Comparison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs | European Heart Journal Supplements | 2001 | 45 |
| 24 | Screening strategies for pulmonary arterial hypertension | European Heart Journal Supplements | 2019 | 44 |
| 25 | Management of carotid stenosis for primary and secondary prevention of stroke: state-of-the-art 2020: a critical review | European Heart Journal Supplements | 2020 | 43 |
| 26 | Heterogeneity of cellular repolarization in LQTS: the role of M cells | European Heart Journal Supplements | 2001 | 42 |
| 27 | Cardiac rehabilitation for coronary patients: lifestyle, risk factor and therapeutic management. Results from the EUROASPIRE II survey | European Heart Journal Supplements | 2004 | 40 |
| 28 | Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) | European Heart Journal Supplements | 2007 | 40 |
| 29 | Principles and usefulness of the cardio-ankle vascular index (CAVI): a new global arterial stiffness index | European Heart Journal Supplements | 2017 | 39 |
| 30 | The role of the exogenous pathway in hypercholesterolaemia | European Heart Journal Supplements | 2001 | 38 |
| 31 | Reverse remodeling in heart failure ? fact or fiction? | European Heart Journal Supplements | 2004 | 38 |
| 32 | Cholesterol absorption inhibition: filling an unmet need in lipid-lowering management | European Heart Journal Supplements | 2001 | 37 |
| 33 | Changes in cardiac metabolism: a critical step from stable angina to ischaemic cardiomyopathy | European Heart Journal Supplements | 2001 | 37 |
| 34 | Sexual activity and cardiovascular risk | European Heart Journal Supplements | 2002 | 37 |
| 35 | The burden of comorbidities in pulmonary arterial hypertension | European Heart Journal Supplements | 2019 | 37 |
| 36 | Long COVID: long-term effects? | European Heart Journal Supplements | 2021 | 37 |
| 37 | EUROACTION: A European Society of Cardiology demonstration project in preventive cardiology.: A cluster randomised controlled trial of a multi-disciplinary preventive cardiology programme for coronary patients, asymptomatic high risk individuals and their families. Summary of design, methodology and outcomes | European Heart Journal Supplements | 2004 | 34 |
| 38 | Ageing, demographics, and heart failure | European Heart Journal Supplements | 2019 | 34 |
| 39 | Pharmacology of ezetimibe | European Heart Journal Supplements | 2002 | 33 |
| 40 | Heart rate management in coronary artery disease: the CLARIFY registry | European Heart Journal Supplements | 2009 | 32 |
| 41 | Defining structural heart disease in the adult patient: current scope, inherent challenges and future directions | European Heart Journal Supplements | 2010 | 32 |
| 42 | Understanding acute heart failure: pathophysiology and diagnosis | European Heart Journal Supplements | 2016 | 32 |
| 43 | ANMCO/AIAC/SICI-GISE/SIC/SICCH Consensus Document: percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation patients: indications, patient selection, staff skills, organisation, and training | European Heart Journal Supplements | 2017 | 32 |
| 44 | Pharmacological properties of betrixaban | European Heart Journal Supplements | 2018 | 32 |
| 45 | Intensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA (GELIA 5) | European Heart Journal Supplements | 2001 | 31 |
| 46 | Increased heart rate as a risk factor for cardiovascular disease | European Heart Journal Supplements | 2003 | 31 |
| 47 | Ezetimibe: efficacy and safety in clinical trials | European Heart Journal Supplements | 2002 | 30 |
| 48 | Are the effects of statins on HDL-cholesterol clinically relevant? | European Heart Journal Supplements | 2004 | 30 |
| 49 | Current evidence on fast track cardiac recovery management | European Heart Journal Supplements | 2017 | 30 |
| 50 | ANMCO/SIC/SICI-GISE/SICCH Executive Summary of Consensus Document on Risk Stratification in elderly patients with aortic stenosis before surgery or transcatheter aortic valve replacement | European Heart Journal Supplements | 2017 | 30 |
